Skip to main content

Table 4 Association of clinicopathological and treatment characteristics with time to tumor progression (univariate analysis)

From: Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Parameter   Patients (total) Patients (progressed) Time to progression (years) p-value
TNM status at diagnosis T0-T1 77 28 5.10 4.13- n.e. 0.1423
T2-T4 176 92 4.06 3.56-7.74
  N0 74 37 4.11 3.30-6.05 0.2813
N1-N3 165 75 5.06 4.05-9.76
  M0 171 79 5.06 4.05-9.70 0.2367
M1 64 31 4.39 3.51-6.58
Grading G1-G2 132 63 4.13 3.55-6.05 0.3122
G3 118 55 5.06 4.04-9.53
Disease-free survival 0-5 years 203 91 5.12 4.11-8.72 0.2183
>5 years 56 32 3.46 3.00-4.44
Hormone receptor status ER negative 109 48 5.96 4.04-9.53 0.1876
ER positive 148 73 4.13 3.55-6.05
  PR negative 132 61 5.06 4.05-6.58 0.6547
PR positive 120 56 4.11 3.53-9.70
  ER and PR negative 94 42 5.06 4.04-9.53 0.3789
ER or PR positive 157 75 4.18 3.56-6.58
Age at trastuzumab start < 50 years 70 32 5.96 4.11-9.76 0.0744
≥50 years 198 94 4.20 3.56-6.05
ECOG status at trastuzumab start 0 115 54 4.61 3.91-9.76 0.0812
1-4 116 59 4.05 3.44-5.96
Site of recurrence at trastuzumab start locoregional      0.1156
recurrent only 55 22 9.70 3.63-9.70
Bone metastases only 41 21 4.05 3.30-n.e.
Visceral metastases 139 69 4.39 3.55-6.58
Initial response to trastuzumab treatment Complete remission 48 16 8.72 4.46-9.76 0.0571
Partial remission 80 46 4.03 3.50-4.41
Stable disease 82 37 4.66 3.56-n.e.
Interruption of trastuzumab treatment no therapy interruption 251 109 5.13 4.11-9.53 0.0005
therapy interruption 14 14 3.51 2.36-4.44